

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representations to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



BBI LIFE SCIENCES CORPORATION

BBI 生物科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1035)

VOLUNTARY ANNOUNCEMENT

CAPITAL INCREASE TO A BIOTECH COMPANY

This announcement is made by BBI Life Sciences Corporation (the “**Company**”), together with its subsidiaries (the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the recent business development of the Group.

Capital Increase Agreement

The board of directors of the Company (the “**Board**”) is pleased to announce that on 23 March 2016, Sangon Biotech Engineering (Shanghai) Company Limited (“**Sangon Biotech**”), an indirect subsidiary of the Company, entered into a capital increase agreement (the “**Capital Increase Agreement**”) with the shareholders of Shanghai Youlong Biotech Co., Ltd (“**Youlong Biotech**”). Pursuant to the Capital Increase Agreement, Sangon Biotech will invest RMB9,600,000 (the “**Investment**”) to Youlong Biotech, of which RMB1,030,000 will be injected into the registered capital of Youlong Biotech. The remaining RMB8,570,000 will be credited to the capital reserve of Youlong Biotech.

In accordance with the Capital Increase Agreement, the Investment will be injected by three installments, provided that Youlong Biotech completed the relevant committed results as required under the Capital Increase Agreement (the “**Committed Results**”). If Youlong Biotech completed the Committed Results on 31 December 2016, Sangon Biotech will inject the investment in full according to the Capital Increase Agreement, and Sangon Biotech will then hold approximately 34% of the total registered capital of Youlong Biotech. The Company will make a relevant announcement in time according to the actual situation of the investment injection.

Pursuant to the Capital Increase Agreement, if Youlong Biotech cannot attain the basic listing requirements of the National Equities Exchange and Quotations in China by the end of Year 2018, then Sangon Biotech has the right to require the controlling shareholders of Youlong Biotech to redeem all the shares held by Sangon Biotech in Youlong Biotech. The calculation of the price of redemption shall be based on the fair value of Youlong Biotech as at 31 December 2018, provided by qualified independent auditor, multiplied by the percentage of the total shares held by Sangon Biotech.

General Information of Youlong Biotech

The major products and services of Youlong Biotech are provision of food safety and biosafety rapid detection products and full chain antibody technology services, including genetically modified ingredient identification strip, mycotoxin detection kits, etc. The Youlong Biotech's major clients cover agricultural product deep processing enterprises, tertiary education institutes and scientific research institutes.

Reasons for and Benefit of Entering into the Capital Increase Agreement

The Company believes that the equity participation in Youlong Biotech will further enlarge the products and services portfolio of the Group, expand the scope of customers and varieties of businesses, therefore is in line with the established development strategy of the Group.

As the applicable percentage ratios of the above-mentioned transaction are lower than 5%, such transaction is expected from complying with the notification, announcement and shareholders' approval requirements under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This announcement is made by the Company on a voluntary basis, for the purpose of informing the investors about the recent business development of the Group.

By order of the Board
BBI Life Sciences Corporation
Wang Qisong
Chairman

Hong Kong, 30 March 2016

As at the date of this announcement, the Board comprises Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin as executive directors; Mr. Hu Xubo as non-executive director; and Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun as independent non-executive directors.